-
Budget Impact Analysis Presented At IMKASID 2025 Shows Opportunity To Reduce Budgetary Pressures And Improve Treatment Accessibility With Ustekinumab Biosimilars In Europe
11 Apr 2025 12:06 GMT
… and Team Leader of Medical & Lifecycle Safety … with reference ustekinumab having Crohn’s disease (CD), psoriasis (PsO), … each indication. Treatment costs of reference ustekinumab and biosimilars were … adverse events (AEs), adverse drug reactions (ADRs) and …
-
Infection Risk and Vaccination in the Management of Psoriasis: Considerations for Biologic Therapy
10 Apr 2025 22:34 GMT
… up to January 2025 using Medical Subject Headings (MeSH) … pivotal Phase 3 clinical trials evaluating the efficacy and … of anti-TB treatment toxicity or drug-drug interactions; in those … in the setting of ustekinumab treatment for psoriasis. JAAD Case Rep. …
-
JNJ-2113 for plaque psoriasis demonstrates clear skin in 75% of adolescents
10 Apr 2025 20:36 GMT
… the once daily pill achieved an Investigator… Medicine, and in ICONIC-LEAD trial presenter. “Young patients with plaque psoriasis … quot; added Eichenfield.
Treatment with the investigational, … ustekinumab in participants with moderate-to-severe plaque psoriasis …
-
Samsung Bioepis' Ustekinumab Biosimilars Budget Impact Analysis in Europe Presented at IMKASID 2025
10 Apr 2025 15:51 GMT
… and Team Leader of Medical & Lifecycle Safety … with reference ustekinumab having Crohn’s disease (CD), psoriasis (PsO), … each indication. Treatment costs of reference ustekinumab and biosimilars were … adverse events (AEs), adverse drug reactions (ADRs) and …
-
Global Biotechnology Market Size to Reach USD 5,036.46 Bn by 2034, Growing at 12.5% CAGR, Says Healthcare Experts
10 Apr 2025 15:11 GMT
… Biotechnology research involves the development of personalized medicines … It accelerates the drug discovery and development … FDA approval to launch the biosimilar version of Stelara (Ustekinumab) for the treatment … , and plaque psoriasis. The company launched …
-
Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill
10 Apr 2025 12:52 GMT
… & Johnson Innovative Medicine. "These data underscore … ustekinumab in participants with moderate-to-severe plaque psoriasis. … Therapeutics, Inc. and Janssen Biotech, Inc., a Johnson … treated, and cured, where treatments are smarter and less …
-
CEOs defend their PBMs. Don’t believe it, says a critic
11 Apr 2025 17:49 GMT
… point of drug acquisition or drug negotiation that … pharmaceutical companies’ biosimilars for Humira (adalimumab) and Stelara (ustekinumab). … based solution for Medicare and
Medicaid markets.
The second … easier for patients and doctors, improve efficiency and …
-
US Pharmaceutical Pipeline Expands With Innovation and Competition
09 Apr 2025 04:53 GMT
… embolism.
Other branded medicines with new indications … roflumilast (Zoryve) for scalp psoriasis, ruxolitinib (Opzelura) for … early movement in the ustekinumab space, in which … L, Casberg J. Drug pipeline: traditional pharmaceuticals (brands and generics …
-
Environmental Factors Impact Psoriasis Severity
08 Apr 2025 23:30 GMT
… MORE: Biosimilar Ustekinumab-Kfce Shows Equivalence to Stelara
While psoriasis can serve … and assessing how they impact treatment strategies and patient adherence.
In … : Sign up for our free Drug Topics newsletter and get the …
-
Real-World Experience of Bimekizumab in a Cohort of 109 Patients Over 48 Weeks and Identification of Predictive Factors for an Early Super Response and Risk of Adverse Events
11 Apr 2025 12:55 GMT
… use of medical records for research … psoriasis: a retrospective multicenter 36-week real-life study. Pharmaceuticals … treatment effects of secukinumab versus ustekinumab in patients with moderate to severe psoriasis … to-severe psoriasis. J Drugs Dermatol. 2020 …
About
© 1995-2025